Clinical Trial Update: Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of adjunctive troriluzole for obsessive-compulsive disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• Troriluzole (troriluzole)

Snippet

Sponsor: Biohaven Pharmaceuticals, Inc. | Conditions: Obsessive Compulsive Disorder | Phase 3 | Status: TERMINATED